Adaptimmune Therapeutics plc (ADAP)

The chart shows the growth of $10,000 invested in Adaptimmune Therapeutics plc in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $681 for a total return of roughly -93.19%. All prices are adjusted for splits and dividends.

Adaptimmune Therapeutics plc had a return of -25.34% year-to-date (YTD) and -50.00% in the last 12 months. Over the past 10 years, Adaptimmune Therapeutics plc had an annualized return of -28.95%, while the S&P 500 had an annualized return of 8.51%, indicating that Adaptimmune Therapeutics plc did not perform as well as the benchmark.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Adaptimmune Therapeutics plc Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Adaptimmune Therapeutics plc. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Adaptimmune Therapeutics plc is 96.57%, recorded on Nov 15, 2019. The portfolio has not recovered from it yet.

Current Adaptimmune Therapeutics plc volatility is 66.59%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.